- Conditions
- SLE (Systemic Lupus), Chronic Pain
- Interventions
- MiPAL
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 561
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Medi-546, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 27 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Diego, California • Atlanta, Georgia + 5 more
- Conditions
- Systemic Lupus Erythematosus, Widespread Pain, Fibromyalgia
- Interventions
- Milnacipran
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Spondyloarthropathy, Vasculitis
- Interventions
- VR-Biofeedback
- Device
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Beverly Hills, California
- Conditions
- Nephrotic Syndrome, Systemic Lupus Erythematosus
- Interventions
- prednisone, cyclophosphamide, cyclosporin A
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1986 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Cenerimod, Placebo
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
- Conditions
- SLE
- Interventions
- Not listed
- Lead sponsor
- Stacy Ardoin MD
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Telitacicept, Placebo
- Biological · Drug
- Lead sponsor
- Vor Biopharma
- Industry
- Eligibility
- 12 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Hemet, California • Menifee, California • Rockford, Illinois + 1 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue
- Interventions
- RAYOS, Prednisone
- Drug
- Lead sponsor
- Ampel BioSolutions, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 15 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 100 mg SC
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Long Beach, California • Tampa, Florida + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Lupus Nephritis
- Interventions
- Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 11
- States / cities
- Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- DS-7011a, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Long Beach, California • San Antonio, Texas
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis
- Interventions
- Nonmyeloablative allogeneic stem cell transplant
- Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- AKBM-3031, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Aker BioMarine Human Ingredients AS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
- Conditions
- Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Interventions
- LY2127399, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Counseling intervention, Informational film
- Procedure · Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- [14C]CCX168
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
- Interventions
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Kyverna Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more